The Impact of Semaglutide Combined with Metformin on Glycemic Control and Metabolism in Patients with Type 2 Diabetes Mellitus

Issue  JCB, Volume 30, Number 3, 2025  Article 

Lanmeng Wang
Department of General Practice, Central Hospital Affiliated to Shandong First Medical University, China
Xiaolin Dong
Department of General Practice, Central Hospital Affiliated to Shandong First Medical University, China
Xin Yan
Department of Nuclear Medicine, Central Hospital Affiliated to Shandong First Medical University, China

Abstract:

Objective: This study aimed to evaluate the effect of semaglutide injection (referred to as Ozempic) combined with metformin (MET) on blood glucose control in patients with Type 2 Diabetes Mellitus (T2DM) and to explore its impact on metabolic indicators. Methods: This study was a prospective self-controlled before-and-after study. A total of 50 T2DM patients who visited the Endocrinology Department of Shandong First Medical University Affiliated Central Hospital from February 2023 to February 2024 were selected and followed up. All patients received treatment with Ozempic combined with metformin, with a treatment regimen that included an initial dose of 0.25mg/week, which was increased to 0.5mg/week after the 4th week, and further increased to 1mg/week after the 8th week, with treatment maintained until the end of 32 weeks. Metabolic indicator data, including glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), weight, body mass index (BMI), blood pressure, blood lipids, and liver and kidney function, were collected before and after treatment. Results: After 32 weeks of treatment, the levels of HbA1c and FPG in patients were significantly reduced (P<0.001). Weight and BMI also significantly decreased (P<0.001). Blood pressure and blood lipids were significantly improved (P<0.05). Meanwhile, liver function and kidney function indicators remained stable (P>0.05). Conclusion: The combination of SML and MET treatment significantly improved blood glucose control and metabolic indicators in T2DM patients and had good safety, providing a new treatment option for T2DM patients.

Download PDF